Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 Synergizes With the Histone Deacetylase Inhibitor PXD101 in Induction of Death of Anaplastic Thyroid Carcinoma Cells

被引:29
|
作者
Kim, Si Hyoung [1 ]
Kang, Jun Goo [1 ]
Kim, Chul Sik [1 ]
Ihm, Sung-Hee [1 ]
Choi, Moon Gi [1 ]
Yoo, Hyung Joon [1 ]
Lee, Seong Jin [1 ]
机构
[1] Hallym Univ, Coll Med, Div Endocrinol & Metab, Dept Internal Med, Chunchon, South Korea
来源
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2015年 / 100卷 / 02期
基金
新加坡国家研究基金会;
关键词
CANCER-CELLS; HSP90; INHIBITORS; ANTITUMOR-ACTIVITY; PROSTATE-CANCER; LEUKEMIA-CELLS; SURVIVIN; HEAT-SHOCK-PROTEIN-90; TUMORS; SENSITIVITY; DOXORUBICIN;
D O I
10.1210/jc.2014-3101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: The influence of the novel heat shock protein 90 (hsp90) inhibitor NVP-AUY922 (AUY922) on anaplastic thyroid carcinoma (ATC) cells has not been investigated. Objective: The effect of AUY922 alone or in combination with the histone deacetylase inhibitor PXD101 on survival of ATC cells was evaluated. Results: In ATC cells, AUY922, compared with 17-allylamino-17-demethoxygeldanamycin, herbimycin A and radicicol, potently lead to growth inhibition and cell death with cleavage of caspase-3 and poly (ADP-ribose) polymerase (PARP) and concomitant changes in expression of hsp90 client proteins. After treatment of both AUY922 and PXD101, compared with treatment of AUY922 or PXD101 alone, the percentage of nonviable cells, annexin V-stained cells, and cytotoxic activity increased. All of the combination index values were lower than 1.0, suggesting the synergism between AUY922 and PXD101 in induction of cell death. In cells treated with both AUY922 and PXD101, compared with cells treated with AUY922 alone, the protein levels of phospho-Akt, cellular inhibitor of apoptosis protein, X-linked inhibitor of apoptosis protein, survivin, ataxia telangiectasia mutated (ATM), and ATM and Rad-3 related (ATR) decreased, whereas those of acetyl. histone H3, acetyl. histone H4, phospho-histone H2A.X, cleaved DFF45, and cleaved PARP increased. Conclusion: Our results demonstrate that AUY922 potently induces cytotoxicity with concomitant modulation of hsp90 client proteins in ATC cells. Moreover, AUY922 has a synergistic activity with PXD101 in induction of cytotoxicity in conjunction with the inactivation of PI3K/Akt signaling and survivin and the activation of DNA damage response in ATC cells.
引用
收藏
页码:E253 / E261
页数:9
相关论文
共 47 条
  • [1] Synergistic Action of Heat-Shock Protein-90 Inhibitor NVP-AUY922 with Histone Deacetylase Inhibition
    Kaiser, M.
    Lamottke, B.
    Jensen, M. R.
    Quadt, C.
    Garcia-Echeverria, C.
    Mieth, M.
    Heider, U.
    Sezer, O.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S129 - S129
  • [2] Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen
    Tauchi, T.
    Okabe, S.
    Ashihara, E.
    Kimura, S.
    Maekawa, T.
    Ohyashiki, K.
    ONCOGENE, 2011, 30 (24) : 2789 - 2797
  • [3] Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen
    T Tauchi
    S Okabe
    E Ashihara
    S Kimura
    T Maekawa
    K Ohyashiki
    Oncogene, 2011, 30 : 2789 - 2797
  • [4] Combined Effects of novel Heat Shock Protein 90 Inhibitor NVP-AUY922 and Nilotinib in a Random Mutagenesis Screen.
    Tauchi, Tetsuzo
    Okabe, Seiichi
    Ashihara, Eishi
    Kimura, Shinya
    Maekawa, Taira
    Ohyashiki, Kazuma
    BLOOD, 2009, 114 (22) : 1449 - 1449
  • [5] NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis
    Eccles, Suzanne A.
    Massey, Andy
    Raynaud, Florence I.
    Sharp, Swee Y.
    Box, Gary
    Valenti, Melanie
    Patterson, Lisa
    Brandon, Alexis de Haven
    Gowan, Sharon
    Boxall, Frances
    Aherne, Wynne
    Rowlands, Martin
    Hayes, Angela
    Martins, Vanessa
    Urban, Frederique
    Boxall, Kathy
    Prodromou, Chrisostomos
    Pearl, Laurence
    James, Karen
    Matthews, Thomas P.
    Cheung, Kwai-Ming
    Kalusa, Andrew
    Jones, Keith
    McDonald, Edward
    Barril, Xavier
    Brough, Paul A.
    Cansfield, Julie E.
    Dymock, Brian
    Drysdale, Martin J.
    Finch, Harry
    Howes, Rob
    Hubbard, Roderick E.
    Surgenor, Alan
    Webb, Paul
    Wood, Mike
    Wright, Lisa
    Workman, Paul
    CANCER RESEARCH, 2008, 68 (08) : 2850 - 2860
  • [6] Novel Hsp90 Inhibitor NVP-AUY922 Radiosensitizes Prostate Cancer Cells
    Gandhi, N.
    Wild, A. T.
    Aziz, K.
    Chettiar, S.
    Gajula, R.
    Zeng, J.
    Herman, J.
    Deweese, T. L.
    Hales, R.
    Tran, P. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S178 - S178
  • [7] Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells
    Gandhi, Nishant
    Wild, Aaron T.
    Chettiar, Sivarajan T.
    Aziz, Khaled
    Kato, Yoshinori
    Gajula, Rajendra P.
    Williams, Russell D.
    Cades, Jessica A.
    Annadanam, Anvesh
    Song, Danny
    Zhang, Yonggang
    Hales, Russell K.
    Herman, Joseph M.
    Armour, Elwood
    DeWeese, Theodore L.
    Schaeffer, Edward M.
    Tran, Phuoc T.
    CANCER BIOLOGY & THERAPY, 2013, 14 (04) : 347 - 356
  • [8] Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
    Kaiser, Martin
    Lamottke, Britta
    Mieth, Maren
    Jensen, Michael R.
    Quadt, Cornelia
    Garcia-Echeverria, Carlos
    Atadja, Peter
    Heider, Ulrike
    von Metzler, Ivana
    Tuerkmen, Seval
    Sezer, Orhan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (04) : 337 - 344
  • [9] Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells
    S. H. Kim
    J. G. Kang
    C. S. Kim
    S.-H. Ihm
    M. G. Choi
    H. J. Yoo
    S. J. Lee
    Journal of Endocrinological Investigation, 2018, 41 : 677 - 689
  • [10] Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells
    Kim, S. H.
    Kang, J. G.
    Kim, C. S.
    Ihm, S-H
    Choi, M. G.
    Yoo, H. J.
    Lee, S. J.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2018, 41 (06) : 677 - 689